ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European <i>In-Vitro</i>-Diagnostics Regulation.
第一作者:
Florent J L A,Vanstapel
第一单位:
Laboratory Medicine, University Hospital Leuven, Leuven, Belgium.;Department of Public Health, Biomedical Sciences Group, Catholic University Leuven, Leuven, Belgium.
作者:
关键词
AB, accrediting bodyBRCA1/2, breast cancer genes 1 and 2CA, competent authorityCAPA, corrective and preventive actionsCDx, companion diagnosticsCGP, comprehensive genomic profileCRGA, clinically relevant genomic alterationsEEA, European economic areaEFLM, European Federation of Clinical Chemistry and Laboratory MedicineEMA, European Medicines AgencyEU, European UnionEuropean Regulation 2017/746 on In-Vitro-Diagnostic DevicesFMEA, failure-mode effects analysisGA, genomic alterationsGDPR, General Data Protection RegulationHI, health institutionHRD, homologous recombination deficiencyHRR, homologous recombination repairISO 15189:2012ISO, International Organization for StandardizationIVDD, In-Vitro Diagnostic Device DirectiveIVDR, In-Vitro Diagnostic Device RegulationLDT, laboratory-developed testMDCG, Medical Device Coordination GroupMSI, micro satellite instabilityMU, measurement uncertaintyNB, notified bodyNGS, next generation sequencingNTRK, neurotrophic tyrosine receptor kinasePARPi, poly (ADP-ribose) polymerase inhibitorsPRRC, person responsible for regulatory compliancePT, proficiency testingRUO, research use onlyRiliB?k, Richtlinie der Bundes?rztekammer zur Qualit?tssicherung Laboratoriums medizinischer UntersuchungenSOP, standard operating procedureTMB, tumor mutational burdenUDI, unique device identifierVAF, variant allele frequencyiQC, internal quality controllaboratory-developed tests for in-house usemethod validation
DOI
10.1515/cclm-2023-0045
PMID
36716120
发布时间
2024-04-23
- 浏览8
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



